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ABSTRACT 
 
 
Breast cancer is one of the most important tumors with high 
morbidity and mortality rates both in the developed and in the 
developing countries. 
This is a retrospective study conducted on the Sudanese 
patients with BC during the period from January 2002 to December 
2005, at the National Health Laboratory in Khartoum, Sudan. 
The study had the objective to review the histopathological 
patterns of BC, and to show the relationships between the histological 
types of the tumor and the age, sex, residency distribution in addition 
to the clinical presentations and the modes of surgical treatment.  
The study included 300 patients, 262 were females and 38 
were males, with a ratio of about 1: 7. The youngest patient was aged 
21 years and the eldest was 77 years old. 
This study showed a high proportion of the disease in younger 
age groups, 37.3% of the patients were below 40   years, with a mean 
age  of 44.45± 13.7 years. 
The study also pointed to the high proportion of BC patients 
coming from the Central and Northern regions. 
 VI
All (100%) of the patients were symptomatic with breast lumps. 
Skin ulceration, nipple retraction and discharge were seen in 
(9%),(13%) and (10%) in order. 
Microscopical examination of the slides identified eight 
histological types of BC. These were IDC (87.3%), ILC (3.7%), 
DCIS(4%), LCIS(1%), papillary carcinoma(2%), tubular 
carcinoma(0.7%), mucinous carcinoma (0.7%) and malignant 
phyllodes tumors(0.7%). 
The study concluded that Sudanese patients share many 
pathological and epidemiological features of the developing countries 
for BC. These include earlier age of onset, higher male- female ratio 
and increased frequency of poor clinical and pathological prognostic 
indicators. 
We emphasis the importance of patients’ education and 
promotion of BC screening program in improving the ultimate outcome 
of this disease.    
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  ﻠﺨـﺹ ﺴـــــــــﺘﻤ
  
ﻴﻌﺘﺒﺭ ﺴﺭﻁﺎﻥ ﺍﻟﺜﺩﻯ ﻤﻥ ﺍﻷﻭﺭﺍﻡ ﺫﺍﺕ ﺍﻷﻫﻤﻴﺔ ﺍﻟﻘﺼﻭﻯ ﺤﻴﺙ ﻴﺘﻤﻴﺯ ﺒﻤﻌﺩﻻﺕ ﻋﺎﻟﻴﺔ ﻤﻥ 
  . ﻀﻴﺔ ﻭﺍﻟﻭﻓﺎﺓ ﻓﻰ ﺍﻟﺩﻭل ﺍﻟﻤﺘﻘﺩﻤﺔ ﻭﺍﻟﻨﺎﻤﻴﺔ ﻋﻠﻰ ﺤﺩ ﺍﻟﺴﻭﺍﺀﺍﺍﻷﻤﺭ
ﺩﺭﺍﺴﺔ ﺍﺴﺘﻘﺼﺎﺌﻴﺔ ﺇﻟﻰ ﺍﻟﻭﺭﺍﺀ ﻋﻥ ﺴﺭﻁﺎﻥ ﺍﻟﺜﺩﻯ ﻋﻨﺩ ﺍﻟﻤﺭﻀﻰ ﺍﻟﺴﻭﺩﺍﻨﻴﻴﻥ ﺃﺠﺭﻴﺕ ﻓﻰ ﻫﺫﻩ 
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ﺭﺍﺕ ﺍﻟﻤﺭﻀﻴﺔ ﻓﻰ ﺍﻷﻨﺴﺠﺔ ﻓﻰ ﺴﺭﻁﺎﻥ ﺍﻟﺜﺩﻯ ﻭﺃﻴﻀﺎﹰ ﺒﺤﺙ ﻴ ﺇﻟﻰ ﻤﺭﺍﺠﻌﺔ ﺍﻟﺘﻐﺔﻫﺩﻓﺕ ﺍﻟﺩﺭﺍﺴ
ﻋﻼﻗﺔ ﺍﻷﻨﻭﺍﻉ ﺍﻟﻨﺴﻴﺠﻴﺔ ﻟﻠﻭﺭﻡ ﻤﻊ ﻜل ﻤﻥ ﺍﻟﻌﻤﺭ، ﺍﻟﺠﻨﺱ ﻭﺍﻟﺴﻜﻥ  ﺒﺎﻹﻀﺎﻓﺔ ﺇﻟﻰ ﺍﻟﻌﻼﻤﺎﺕ ﺍﻟﺴﺭﻴﺭﻴﺔ 
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ﺔ ﺍﻟﻌﺎﻟﻴﺔ ﻟﻤﺭﻀﻰ ﺴﺭﻁﺎﻥ ﺍﻟﺜﺩﻯ ﻓﻰ ﺍﻟﻔﺌﺎﺕ ﺍﻟﻌﻤﺭﻴﺔ ﺍﻟﺼﻐﺭﻯ، ﺒﻭﻗﺩ ﺃﺒﺭﺯﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﻨﺴ
ﻟﻜل ﺍﻟﻔﺌﺎﺕ ﻫﻭ  ﻤﺘﻭﺴﻁ ﺍﻟﻌﻤﺭ ﻓﻴﻤﺎ ﻜﺎﻥ ﺴﻨﺔ، 04ﻤﻥ ﺍﻟﻤﺭﻀﻰ ﺘﺤﺕ ﻋﻤﺭ % 3.73ﺤﻴﺙ ﻜﺎﻥ 
 .  ﺴﻨﺔ31 ± 54.44
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  .ﻭﺍﻟﺸﻤﺎﻟﻴﺔ  ﻤﻥ ﺍﻟﺒﻼﺩ
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INTRODUCTION & LITRATURE REVIEW 
 
Breast cancer (BC) is one of the most common human 
neoplasms, accounting for approximately one third of all cancers in 
females.(1) It is associated with the western lifestyle, so has higher 
incidence in North America, Europe and Australia.(2) In Africa it is the 
second most common malignancy in females after the carcinoma of 
the cervix.(3) As a cause of cancer death it ranks second after the 
lung cancer.(5)  
In Sudan, according to reports derived from the department 
of medical statistics and registration of NHC and RICK, breast 
cancer is estimated to account for 33.8% of all cancer cases.(4) 
Most of the breast cancers are invasive and the majorities 
(70%-80%) are adenocarcioma, arising from the ductal lobular units 
of the breast.(6) About (40%-70%) being invasive ductal carcinoma(7), 
followed by invasive lobular carcinoma (5%-15%)(8,9,10) and tubular 
carcinoma (2%-7%).(11) Rare forms include medullary carcinoma 
(1%-5%), mucinous (2%), neuroendocrine (1%-2%) and invasive 
papillary carcinoma (1%).(12) In addition are the non epithelial 
malignant tumors as malignant lymphoma, mesenchymal and 
metastatic tumors.(13, 14,15) 
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Breast cancer is rare before the age of 25 years, its peak age 
at the time of diagnosis is 58 years. (5) Male breast cancer is 
extremely rare; the male: female ratio being 1-2:100. This ratio is 
reported higher in African and black populations.(16,17) 
Breast cancer is recognized as having familial tendency.(18) 
Genes implicated include BRCA 1 and BRCA 2 genes 
mutations.(19,20) Hormonal, nutritional and other environmental 
factors are also established etiological factors.(21,22,23,24)High risk 
precursor lesions of invasive cancer include ductal carcinoma in 
situ(25,26) fibrocystic disease with atypical ductal hyperplasia (27,28) and 
lobular carcinoma in situ (29,30). While low risk lesions include benign 
myoepithelial and fibroepithelial lesions as fibroadenoma.(31) 
Breast cancer is diagnosed and screened basing on the triple 
assessment (clinical, radiological and pathological), while surgical 
and adjuvant medical modalities are tried to manage this 
disease.(119) 
1.1 Normal anatomy and histology of the breast: 
1.1.1 Gross anatomy: 
Breast, or mammary gland, is a modified apocrine sweat 
gland lying in the anterior chest wall. It extends from the second to 
the sixth rib, lying on the superficial fascia of the chest wall, with a 
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small axillary tail extending upwards and laterally into the deep 
fascia(33) After puberty in females, the breast enlarges and takes its 
spherical shape with a central nipple surrounded by colored 
areola.(32) The breast consists fifteen to twenty lobes radiating from 
the nipple.(33)  
  1.1.2 Blood supply and lymphatic draining:  
Arterial blood supply to the breast is from the perforating 
branches of the internal thoracic artery and the intercostal arteries, 
the axillary artery also supplies the breast via its lateral thoracic and 
thoracoacromial branches .The veins correspond to the arteries.(34) 
The lymphatic draining of the mammary glands is very 
important clinically because it is related to cancer spread, then 
staging and prognosis.(35) The lateral quadrants of the breast drain 
into the anterior axillary or pectoral lymph nodes. The medial 
quadrants drain by mean of vessels that pierce the intercostal space 
and enter the internal thoracic lymph nodes within the thorax. Some 
vessels drain in the posterior intercostal nodes; while some may 
communicate with the opposite breast.(36) 
1.1.3 Normal histology: 
The functional unit of the breast is the ductal lobular unit 
(DLU).(37) Composed of acini, interlobular stroma and intralobular 
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ducts which bud from subsegmental ducts that drain into segmental 
ducts. The segmental ducts with their branches and interlobular 
stroma  and fatty tissue form a lobe .The ducts are lined by two 
layers of epithelium; an inner cuboidal or columnar and outer 
discontinuous layer of contractile myoepithelial cells. The epithelium 
is invested in continuous basement membrane.(37) Most of the 
interlobular stroma consists of dense fibrous tissue admixed with 
adipose tissue .The intralobular stroma is delicate myxomatuos 
tissue containing scanty lymphocytes.(37) 
1.2 Breast pathology: 
1.2.1 Congenial anomalies: 
    All are very rare and impose no diagnostic difficulties. 
They includes: -(72)   
• Supernumerary nipples or breasts.  
• Accessory axillary breast tissue. 
• Congenital inversion of nipples. 
• Juvenile hypertrophy (Macromastia)  
1.2.2 Inflammatory conditions: 
Are rare but can mimic breast cancer both clinically and 
histologicaly.(73) They include:-         
• Acute mastitis: present as painful mass, usually during lactation.  
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• Tuberculous mastitis: shows typical granuloma. Clinically may 
mimic advanced cancer.(74)  
• Periareolar mastitis (Zuska's disease): is a periareolar abscess 
associated with squamous metaplasia of the lactiferous ducts.(75) 
• Mammary duct ectasia: Is dilatation of the large ducts with 
accumulation of fatty depresses, calcification and florid 
inflammatory reaction with no epithelial hyperplasia. May mimic BC 
by causing nipple retraction. (76) 
• Fat necrosis: Characterized by foamy macrophages infiltrating 
necrotic adipose tissue and dense inflammatory cells infiltration. 
Like cancer, can cause solid mass and skin retraction. (77)     
• Lymphocytic mastopathy: characterized by dense peri and 
intralobular lymphocytic infiltration associated with lobular atrophy 
and sclerosis. Usually mistaken as breast lymphoma.(78)    
• Granulomatous lobular mastitis: characterized by non caseating 
granuloma confined to one lobule.(79) 
1.2.3 Benign epithelial lesions:  
• Non proliferative breast changes (fibrocystic changes) present 
clinically as breast lumps mimicking carcinoma. Morphological 
changes include cyst formation often with apocrine metaplasia, 
fibrosis and adenosis.(80)  
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•  Proliferative breast diseases without atypia. These lesions 
include: 
A) Simple epithelial hyperplasia: Characterized by proliferation of 
the ductal epithelium to more than two cell layers without 
cellular abnormalities.(81) 
B) Sclerosing adenosis: denotes marked increased in the number    
of the   acini with their compression in the central part of the 
lesion with calcification, mimicking the invasive carcinoma.(82) 
C) Radial scar is a stellated lesion characterized by a nidus of 
glands in hyalinized stroma. This condition can simulate breast 
cancer both in morphology and in mammography. (83)            
• Proliferative breast diseases with atypia: 
A) Atypical ductal hyperplasia (ADH): characterized by epithelial 
proliferation with incompletely monomorphic cell population, 
regular cell placement and round lumen, markedly simulating 
the DCIS with some quantitative and qualitative differences. (84)   
B) Atypical lobular hyperplasia (ALH): show monomorphic small 
rounded loosely cohesive cells, partially filling the lobules with 
less than 50% of the acini is fully distended, quantitative 
difference from the LCIS. (47)           
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1.2.4 Breast tumors: 
 (WHO histological classification of breast tumors) (Appendix 2) 
I. Epithelial tumors:  
1.1 Invasive ductal carcinoma, not otherwise specified (NOS). 
1.1.1 Mixed type carcinoma. 
1.1.2 Pleomorphic carcinoma. 
1.1.3 Carcinoma with osteoclastic giant cells.  
1.1.4 Carcinoma with chondrocarcinomatous feature. 
 1.1.5 Carcinoma with melanotic feature.  
   1.2 Invasive lobular carcinoma.  
   1.3 Tubular carcinoma.  
   1.4 Invasive cribriform carcinoma.  
   1.5 Medullary carcinoma.  
   1.7 Mucinous carcinoma and other tumors with abundant mucin        
 1.7.1 Mucinous carcinoma. 
 1.7.2 Cystadenocarcinoma and columnar cell mucinous 
carcinoma.    
1.7.3 Signet ring cell carcinoma. 
1.8 Neuroendocrine tumors.  
1.8.1 Solid neuroendocrine tumors. 
1.8.2 Atypical carcinoid tumors. 
1.8.3 Small cell / oat cell tumors. 
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1.8.4 Large cell neuroendocrine carcinoma. 
1.9 Invasive papillary carcinoma. 
1.10 Apocrine carcinoma. 
1.11 Metaplastic carcinoma. 
1.11.1 Pure epithelial metaplastic carcinoma. 
1.11.1.1 Squamous cell carcinoma. 
1.11.1.2 Adenosquamous carcinoma with spindle 
cell metaplasia. 
1.11.1.3   Adenosquamous carcinoma. 
1.11.1.4   Mucoepidermoid carcinoma. 
1.11.2 Mixed epithelial cell / mesenchymal tumors. 
1.12 Lipid rich carcinoma.  
1.13 Secretory carcinoma.  
1.14 Oncocytic carcinoma. 
1.15 Adenoid cystic carcinoma.  
1.16 Acinic cell carcinoma.  
1.17 Glycogen-rich clear cell carcinoma. 
1.18 Sebaceous carcinoma.  
1.19 Inflammatory carcinoma. 
1.20 Lobular neoplasia. 
1.20.1 Lobular carcinoma in situ. 
1.21 Intralobular proliferative lesions. 
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1.21.1 Usual ductal hyperplasia. 
1.21.2 Flat epithelial atypia. 
 1.21.3 Atypical ducal hyperplasia. 
  1.21.4 Ductal carcinoma in situ. 
1.22 Microinvasive carcinoma.  
1.23 Inraductal papillary neoplasia.  
         1.23.1Central papilloma. 
         1.23.2 Peripheral papilloma. 
         1.23.3 Atypical papilloma. 
         1.23.4 Intraductal papillary carcinoma. 
         1.23.5 Intracystic papillary carcinoma. 
1.24 Benign epithelial proliferations. 
       1.24.1 Adenosis including variants.  
                  1.24.1.1 Sclerosing adenosis. 
                  1.24.1.2 Apocrine adenosis. 
                  1.24.1.3 Blunt ducts adenosis. 
                  1.24.1.4 Microglandular adenosis. 
                  1.24 1.5 Adenomyoepithelial adenosis.  
  1.24.2 Radial scar / complex sclerosing lesions.  
         1.24.3 Adenomas. 
                  1.24.3.1 Tubular adenoma. 
                  1.24.3.2 Lactating adenoma. 
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                  1.24.3.3 Apocrine adenoma.  
                  1.24.3.4 Pleomorphic adenoma. 
                  1.24.3.5 Ductal adenoma.  
2. Myoepithelial lesions   
2.1 Adenomyoepithelial adenosis. 
          2.2 Adenomyoepithelioma.  
 2.3 Malignant myoepithelioma. 
3. Mesenchymal tumors   
          3.1 Haemangioma. 
          3.2 Haemangiopericytoma.  
          3.3 Psedoangiomatous stroma hyperplasia.  
          3.4 Myofibroblastoma. 
          3.5 Fibromatosis. 
          3.6 Inflammatory myofibroblastic tumors. 
          3.7 Lipoma. 
          3.8 Angiolipoma.  
          3.9 Granular cell tumors. 
          3.10 Neurofibroma. 
          3.11 Schwannoma.  
          3.12 Angiosarcoma.  
          3.13 Liposarcoma.  
          3.14 Rhabdomyosarcoma. 
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          3.15 Osteosarcoma. 
 3.16 leiomyoma. 
   3.17 Leiomyosarcoma. 
4. Fibroepithelial tumor  
          4.1 Fibroadenoma  
          4.2 Phylloides tumors 
                4.2.1 Benign  
                4.2.2 Borderline  
                 4.2.3 Malignant 
4.3 Periductal stromal sarcoma, low grade 
4.4 Mammary hamartoma 
5. Tumors of the nipple  
          5.1 Nipple adenoma 
          5.2 Syringiomatuos adenoma 
          5.3 Paget's disease of the nipple 
6. Malignant lymphoma  
          6.1 Diffuse large B-cell lymphoma  
          6.2 Burkett's lymphoma  
          6.3 Extra nodal B-cell lymphoma of MALT type 
          6.4 Follicular lymphoma 
7. Metastatic tumors. 
8. Tumors of the male breast.  
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           8.1 Gynaecomastia 
           8.2 Carcinoma  
                   8.2.2 Invasive 
                   8.2.2 In situ 
1.3 Epidemiology and risk factors of breast cancer: 
1.3.1 Epidemiology:  
Breast cancer is the most common non skin malignant tumor 
and the leading cause of cancer death in women, with more than 
1000.000 cases occurring world wide annually. (39)  In United States, 
it was reported that each year approximately 100.000 new cases are 
diagnosed and around 30.000 die from the disease. (40)  The life time 
risk is about 13% for females and around 0.11%for males. (41)  The 
incidence is high in America and North Europe (about 9.4 new cases   
pre 100.000 women each year).(41)  In America the detection and 
then incidence of BC increased due to wide spread of 
mammography.(39) Intermediate incidence is seen in Southern 
European and Latin American countries. The incidence of BC is 
relatively low in African and Asian countries. However, it is second 
most common malignancy in an African female population after 
cervical cancer. (42)   
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In Sudan, breast cancer is the most common malignant 
tumor in females .It is the leading cause of cancer mortality among 
the Sudanese females.(4)   
1.3.2. Risk factors:- 
Proved risk factors of BC include familial & genetic, hormonal 
and environmental factors.(40,43) It has been proposed that the 
common dominator for these risk factors is strong and/or prolonged 
estrogen stimulation operating on susceptible genetic back 
ground.(43)     
1- Age: 75% of breast cancer occurs after the age of 50 years.(44) 
The mean age for breast cancer in some Arab and African 
countries was found 48.3 years.(42)   
2- Age at menarche: less than 11 years has 20% increased risk.(45)  
3- Parity: women with first full pregnancy at age younger than 20 
years have half risk of nulliparous and older women.(45)  
4- Family history: positive family history is found in 13% of women 
with BC.(46)Some studies found that women who have first degree 
relatives with BC have increased risk by two to three times to 
develop the disease.(46)  
5- Breast biopsy: risk increases by 4-5 times with prior breast 
biopsies showing atypical ductal or lobular hyperplasia.(47)  
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6- Race: the risk of developing BC in next 20 years at the age of 50 
years is 1 in 15 in Caucasian, 1 in 20 in African American, 1 in 25 
in Asian/Pacific Islanders and 1 in 27 in Hispanics. (48)  
7 - Estrogen exposure: decrease in endogenous estrogen reduces 
the risk by up to 75 %.(49) While many studies regarding oral 
contraceptive use show no increase risk to BC. (50, 51)  
8- Radiation exposure: therapeutic radiation for lymphoma 
increase the risk by 20%- 30 %.( 52) 
Other recognized but difficult to quantity factors include:  
1- Breast feeding some studies pointed that breast feeding reduces 
the risk of breast cancer.(53)  
2- Geographical influence. 
3- Diet and alcohol.(44) 
4- Environmental toxins.  
5- Tobacco. (43) 
6- Obesity and anthropometric indices.  
7- Exercise.(43) 
1.4 Genetics and Pathogenesis: 
Breast cancer has multifactorial aetiology involving genetic, 
environmental and hormonal factors.(54)   
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Familial breast cancer is related to genetic alterations 
including inactivation of oncosupressor genes or over expression of 
oncogenes .Well studied are BRCA-1 and BRCA-2 genes 
mutations.(55)  
BRCA-1 gene is an 81 kb oncosupressor gene located at the 
long arm of the chromosome 17(17q21).(56)  BRCA-1 protein is an 
1863 amino acids phosphoprotien. It functions in transcriptional 
regulation, cell cycle control and chromatin remodeling.(57)  It 
protects the cell from damage by stopping cell cycle.BRCA-1 gene 
mutation carries life time risk for BC of 60% to 80%.(58)  Histological 
patterns of BC associated with BRCA-1 mutations include medullary 
carcinoma and ER –PR and Her 2/ neu negative carcinomas. Other 
cancers include ovarian, prostatic, and colorectal cancers.(55)  
BRCA-2: is an 84 kd gene located at the long arm of the 
chromosome 13(13p12.2).(59) BRCA-2 protein is a 3418 polypeptide. 
It act as DNA repairing factor by binding to BRCA-1 to form a 
nuclear dot complex at the site of DNA repair.(60)  Mutation carries 
60% to 80% risk for BC, with higher association with male breast 
cancer.(61) 
Her-2 neu gene: is an oncogene that encodes a 
transmembrane glycoprotein with tyrosine kinase activity known as 
p185, which belongs to the family of EGFR genes. HER-2/neu is a 
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very good predictor of response to Herceptin, but not to 
chemotherapy or overall survival. It is found in nearly all cases of 
high grade (comedo-type) DCIS, in 20-30% of IDC, and in a smaller 
percent of ILC.(62)  
Other genes: Genes other than BRCA-1 and BRAC-2 
involved in BC susceptibility include the check point kinetic gene 
CHEK2;(63,64) as well as the oncosupressor genes p53, PTEN and 
LKBI/STKII .(65)  While oncogenes include ER, EGFR, RAS, CCND-1 
and other genes.(63)  
Sporadic breast cancers are related more to environmental 
and hormonal factors.(41) Estrogen excess hypothesis stipulates that 
BC risk depend on direct exposure to estrogen.(66) It is said to give 
metabolites that cause mutations or generate DNA damaging free 
radicals.(67) Hormonal action of estrogen also can drive proliferation 
of cancer cells.(67) Estrogen plus progesterone hypothesis highlights 
the role of progesterone in enhancing the action of estrogen.(68, 69) 
1.5 Localization of breast cancer: 
Carcinomas arise from the mammary epithelium and most 
frequently from the TDLU. Studies reported slightly higher frequency 
of BC in the left breast with left to right ratio 1.07 to 1.00.(70, 71) 
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Location of the breast cancer is usually indicated in relation 
to the breast quadrants. 50% are in the upper outer quadrant, 15% 
in the upper inner quadrant, and 10% in the lower outer quadrant, 
5% in the lower inner quadrant, 7% in the central region and 3% are 
multicenteric lesions. 
Bilateral breast cancer is detected in less than 5% of 
patients. A higher percentage being of lobular type.(71)  
1.6 Metastasis and spread of breast cancer: 
Breast cancer may spread via lymphatic and hematogenous 
routes and by direct extension to the adjacent anatomical structures. 
(85) Spread via the lymphatic route is most frequently to the ipsilateral 
axillary lymph nods, internal mammary nodes and other regional 
nodes groups. Most common sites for distant metastasis are bone, 
lung and liver. Unusual sites for metastasis include peritoneal 
surface, gastrointestinal tract and reproductive organs. (86)  
1-7 Diagnosis and screening:  
Breast cancer is best diagnosed by the triple assessment 
including clinical examination, mammography and pathological 
studies.  
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1-7-1 Clinical pictures of breast cancer:   
The majority of breast cancers present symptomatically, but 
introduction of breast screening has led to increasing proportion of 
asymptomatic cases.(87) Clinical signs and symptoms of breast 
cancer include pain (mastalgia), palpable mass or lumpiness, nipple 
discharge and changes, skin changes and others.(87) Pain is present 
in 10% of breast cancer cases, although the majority of the painful 
conditions are benign. Comes second is the palpable mass. The 
frequency of the malignant masses depends on the age, only 10% 
of breast masses in women under the age of 40 years prove 
malignant compared to 60% in women over 50% years.(87) Nipple 
discharge is more indicative of breast cancer in older women and  
when it is spontaneous and unilateral. (87)  Skin changes include peu 
de`orange and ulcerations. Other clinical features of breast cancer 
include upper limb oedema and systemic features of 
malignancy.(88,89)   
1-7-2 Screening of breast cancer:- 
Screening denotes detection of the disease before 
appearance of its signs and symptoms.(90) Breast cancer screening 
program, first introduced in early 1980s, aims at reduction of 
mortality by discovering preclinical breast cancer in asymptomatic 
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patients.(90) It is especially recommended in high risk population 
including women over 40 years and women with strong familial 
tendency.(91) It is estimated that screening of average risk population 
can reduce the mortality by up to 25 %.(92) Clinical screening 
includes breast self examination (BSE) and clinical breast 
examination (CBE) of the breast tissue and axilla to detect any 
palpable mass or LN.(93) Screening mammography is especially 
recommended for women over 40 years. Finding in mammography 
include densities and calcifications.(94)  
1-7-3 Diagnostic studies: 
Histological examination of tissue biopsy is still the gold 
stander in diagnosis of breast cancer.(95) Useful diagnostic tools 
include fine needle aspiration (FNA) cytology, and imaging .Ancillary 
studies include immunohistochemical, cytogenetic and molecular 
biology techniques.(95)  
Tissue biopsy is either obtained surgically (incisional or 
excisional) or by core needle biopsy technique, stained with H&E 
stain with or without other especial stains.(95)  
Fine needle aspiration is cheap and easy to perform, with up 
to 90% diagnostic accuracy rate.(96) Its sensitivity is up to 84%. 
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Diagnostic mammography is performed to clarify breast 
abnormalities and to give additional information about other areas of 
involvement.(97) Other imaging methods include: 
1- Digital mammogram.  
 2- Breast ultrasonography (U/S) and magnetic resonant imaging 
(MRI). 
3- Thermography of the breast. 
4- Computed tomography scan (CT-Scan) and positron emission 
tomography scan (PET- scan)(97).     
1-8 Pathology of the breast cancer  
1-8-1Gross Pathology: 
Most breast cancers are firm to hard moderately defined 
masses, in variable sizes. In later stages they can form exophytic or 
fungating masses with skin ulcerations. In cross section whitish to 
yellow tissue with areas of necrosis are seen, together with small 
pinpoint or streaks of white chalky elastotic stroma.(98) 
1-8-2 Histological Types of Breast cancer (Appendix 2) 
Almost all of the breast cancer are adenocarcioma, arising 
from terminal ductal lobular unit (TDLU).(99)  Other malignancies 
account for less 3%, including squamous cell carcinoma, 
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lymphomas, malignant phyllodes tumors, and other mesenchymal 
tumors.(100)  
Summarized WHO histological classification of Breast 
Cancer:   
1. Noninvasive:  
a. Ductal carcinoma in situ.  
b. Lobular carcinoma in situ.  
2. Invasive:  
a. Invasive ductal carcinoma.  
b. Invasive ductal carcinoma with a predominant intraductal 
component. 
c. Invasive lobular carcinoma.  
d. Mucinous carcinoma.  
e. Medullary carcinoma.  
f. Papillary carcinoma.  
g. Tubular carcinoma.  
h. Adenoid cystic carcinoma.  
i. Secretory (juvenile) carcinoma.  
j. Apocrine carcinoma.  
k. Carcinoma with metaplasia.  
i. Squamous type.  
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ii. Spindle-cell type.  
iii. Cartilaginous and osseous type. 
iv. Mixed type.  
l. Others.   
3. Paget’s disease of the nipple.  
Non invasive carcinoma (Carcinoma in situ): 
•  Ductal carcinoma in situ (DCIS): Account for 15% to 20% of all 
breast cancer where mammography is widely used. (101)  
Histologicaly it is characterized by variable cellular atypia without 
stromal invasion.(102) Architectural patterns of DCIS include 
comedocarcinoma, solid, cribriform, papillary and micropapillary 
types.(102)   
• Lobular carcinoma in situ (LCIS): Represents less than 2% of 
cancer cases.(103)Characterized by intralobular proliferation of 
loosely cohesive cells, with no basement membrane penetration or 
stromal invasion. 40% to 50% of LCIS are bilateral. (104)  
Invasive carcinomas: 
• Invasive ductal carcinoma (IDC): Comprises about 7o% to 90% 
of breast cancer cases. Histologically the tumor cells are arranged 
in cords, nests and trabiculea, or solid syncytial pattern with 
minimal stroma. (105)  Most cases have no specific architecture and 
assigned as IDC not otherwise specified (NOS).Other may take 
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comedo, papillary, cribriform and other patterns seen in DCIS, all 
are characterized by stromal invasion. (105)  
• Invasive lobular carcinoma (ILC): Represents about 5% of 
cases, in histological section, this tumor appear composed of in 
cohesive small round cells disperse through fibrous connective 
tissue, arranged in single files linear cords invading the stroma. 
Other patterns include solid, alveolar and pleomorphic lobular 
carcinoma.(106)  
• Tubular Carcinoma: Composed of single layered open tubules 
with oval or rounded edges.(107)  
• Medullary carcinoma: By definition, this type has syncytial 
architecture, no tubular or glandular structure and diffuse 
lymphoplasmacytic stroma infiltration. The cells are usually round 
with abundant cytoplasm and vesicular nuclei. (108)  
•  Mucinous carcinoma:  Characterized by proliferating clusters of 
small cell floating in lakes of mucin. (109)  
•  Invasive Papillary carcinoma: Histological sections in this type 
show delicate or blunt papillae with focal solid area. Cells typically 
show amphophilic cytoplasm and moderately pleomorphic 
nuclei.(110)     
•  Metaplastic carcinomas: Are heterogeneous group of tumor 
characterized by presence of admixture of adenocarcinoma with 
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dominant areas of spindle cells, squamous and/or mesenchymal 
differentiation. 
•  Paget’s disease of the nipple: Represents less than 2% of the 
cases. It is extension of malignant cells from DCIS into nipple skin 
without crossing the basement membrane. The tumor (Pagetoid) 
cells are large and easily detected. (111)  
•  Carcinoma of male breast: Breast cancer is very rare in males 
with male: female ratio less than 1:100 worldwide.(40)  But higher 
ratio is observed in Africa.(42) However, pathological feature of male 
breast cancer is similar to that in female, although papillary 
carcinoma is more common.(112)  
•  Malignant phyllodes tumors: Characterized by intracanalicular 
growth pattern with leaf-like projection into dilated ducts. It consists 
of epithelial and myoepithelial component and sarcomatous stroma 
with heterogeneous differentiation. 
1-9 Staging of breast cancer:  
 Tumor staging is a numerical description of the degree of 
invasion and metastatic spread of the tumor. Staging of breast 
cancer is valuable both in treatment choice and as a prognostic 
factor. (113)  
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The TNM classification devised by the International Union 
Against Cancer (UICC) and accepted by the American Joint 
Commission on Cancer (AJCC) is a world standard.(113) It is the most 
accurate but too cumbersome and complicated. The TNM is based 
on the clinical features of tumor (T), the regional lymph nodes (N), 
and the presence or absence of distant metastases (M). (114)  
* AJCC stage groupings of breast cancer, based on TNM score (113) 
(Appendix 3) 
Stage 0 Tis, N0, M0 
Stage I T1, N0, M0 
Stage IIA T0, N1, M0 
 T1,N1, M0 
 T2, N0, M0 
Stage IIB T2, N1, M0 
 T3, N0, M0 
Stage IIIA T0, N2, M0 
 T1, N2, M0 
 T2, N2, M0 
 T3, N1, M0 
 T3, N2, M0 
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Stage IIIB T4, Any N, M0 
 Any T, N3, M0 
Stage IV Any T, Any N, M1 
Other staging systems for breast cancer include Manchester 
and the Columbia Clinical Classification (CCC).(113) In the latter 
system, stage A represents a tumor confined to the breast; stage B 
include tumors with clinical axillary lymph node enlargement; stage 
C represents the presence of grave prognostic signs in the breast, 
stage D indicates metastatic disease. 
1-10 Grading of breast cancer:   
Tumor grading is numerical expression of the degree of its 
cellular differentiation.(115)It is based on careful assessment of 
histological section under the microscope. Studies showed    
significant association between the histological grades in invasive 
cancer and the prognosis.(116) So it should be included in minimal 
data set in reporting   breast cancer. Currently used grading system 
is Modified Bloom's and Richardson's system.(118) Other types 
include Elliston and Ellis, Pately and Craft systems. 
Modified Bloom's and Richardson's System: Is based on three 
histological parameters; tubular formation, degree of nuclear 
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pleomorphism and mitotic count.(118) All are estimated under high 
power field (X40); using standard microscope (e.g. Nikon Lab Photo 
with field diameter .59 mm and field area  274mm2). Scoring: 
Tubular formation:                1 – 3 points 
Nuclear pleomorphism:        1 – 3 points  
Mitotic count:                        1 – 3 points 
Final grading classification is obtained by summation of 
these scores:-  
Grade I (well differentiated):                          3 – 5 points 
Grade II (moderately differentiated)               6 – 7 points 
Grade III (poorly differentiated):                     8 – 9 points 
1-11 Treatment of breast cancer:  
The main types of treatments for breast cancer are surgery, 
radiation, chemotherapy and hormonal therapy.(119) Recent 
advances in this field include introduction of immunotherapy and 
gene-targeted therapy.(119) Selection of type of treatment is 
influenced by the age of the patient, the clinical stage of the disease 
(node +ve and node –ve Tumors), pathological characteristics and 
the level of estrogen and progesterone receptors. (120)  
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1-11-1 Surgical treatment (types of operation): 
1- Modified radical mastectomy: denotes removal of the whole 
breast tissue plus axillary fat, fascia and lymph nodes. 
2- Quadrantectomy: is the removal of entire segment of the breast 
which contains the tumor. This is usually accompanied with 
removal of the axillary lymph nodes. 
3- Lumpectomy: denotes removal of the tumor with at least 1 cm of 
normal breast tissue. 
4- Simple mastectomy: removal of the breast tissue without removal 
of the axillary lymph nodes. (121) 
1-11-2 Radiotherapy: 
Usually designed before surgical treatment. (122) 
1-11-3 Chemotherapy: 
Different regimens of cytotoxicity drugs have been applied for 
different stages of breast cancer and in combination with surgery 
and radiotherapy. Drugs given include CMF (Cyclophosphamide, 
Methotrexates and Florouridine) and CA (cyclophosphamide and 
doxorobicine). (123) 
1-11-4 Hormonal therapy: 
Especially useful for estrogen rich tumors, widely used anti- 
estrogen agent is tamoxifen in 20 ml daily dose.(124) 
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Recent adjuvant therapies include aromatase inhibitors as 
Arimidex and gene targeted therapy as Herceptin.(125) 
1-12 Prognosis of breast cancer: 
Prognosis is the ultimate outcome of the disease and is 
usually expressed in crude certain period survival rates and disease 
free survival. (126)  The crude five years survival rate of the breast 
cancer after conventional treatment range varies between 63.5 and 
32.0. (127)  
The prognosis of the breast cancer is influenced by certain 
biological, clinical, immunological and pathological variables (128); the 
main one being the pathological stage of the disease. In addition to 
TNM stage of BC, predictor of tumor invasiveness and metastasis 
include the histological type, angiogenic markers, and markers of 
cell proliferation.(128) While predictors of tumor growth rate are the 
histological grade, ER and PR receptors expression, genetic 
markers as HER2/ neu and EGFR expression and cell proliferation 
markers such as mitotic index, S- phase fraction Ki- 67and 
PCNA.(128) Predictors of efficacy of response to treatment are other 
prognostic factors, including expression of hormone receptors and 
certain genes as HER2/ nue. (128)  
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1-13 Preparation of histological sections: 
        Histological sections taken for diagnosis of breast cancer, as 
other tissues, are first processed to produce slides for microscopical 
examination.  
Steps of routine tissue processing: 
1- Specimen accessioning:  includes specimen reception with 
ensuring of adequate information in the request form and labeling of 
both specimen containers and request form. 
2- Gross examination: performed by a pathologist and include 
description of the specimen and placing all or representing parts of it 
in labeled cassettes. 
3- fixation: means attempt of permanent preservation of the tissue 
by immersing it into a fixative substance. Fixatives are chemicals 
usually belonging to one of these groups: aldehydes, alcohols, 
mercurial, oxidative agents and picrates. 
4- Tissue processing:  aiming to make the tissue amenable for  
subsequent cutting by microtome. Processing include embedding of 
the tissue in paraffin wax, proceeded by tissue dehydration using 
series of alcohol dilutions , then clearing up alcohol by xyline. 
5-Sectioning: is cutting of processed tissue by microtome into small 
(6-8 microns) sections. 
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6- Staining : routine staining is by using Hematoxylin and Eosin 
dyes. Steps of staining include removal of paraffin wax out of the 
tissue then stepped rehydration of the tissue using series of alcohol 
dilutions. 
Hematoxylin is a basic dye and stains the nucleus blue; while Eosin 
is an acidic dye with an affinity for the cytoplasmic components of 
the cell. Both dyes need a mordant, usually metallic ion, for active 
staining. 
7- Coverslippig: includes covering of the stained section with thin 
glass to protect the tissue from being scratched. First the section is 
dehydrated and cleared and then covered with a mounting 
substance. 
         Processing of the histological section from fixation to 
Coverslippig is the function of a histotechnologist, who deliver the 
slide to a pathologist for reading and final reporting. 
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OBJECTIVES 
General objectives: 
To review the clinical, pathological and epidemiological 
features of breast cancer in the study area. 
Specific Objectives: 
1- To review the histological patterns of Breast Cancer among the 
study population. 
2- To determine the histological grades of   breast caner 
according to Modified Bloom's Richardson's grading system, 
among the study population. 
3- To review the clinical presenting features of breast cancer in 
the study population.  
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                 PATEINTS AND METHODS 
 2.1 Study design: 
The study is a descriptive retrospective recorded data -based 
study.  
2.2 Study area: 
The study was conducted at the National Health Laboratory 
(NHL), Department of Histopathology. It is the major public section 
lab in the country, providing nationwide diagnostic, training and 
research services.   
2.3 Study population: 
Cases diagnosed as breast cancer in the department of 
histopathology in the study area, from January 2002 up to 
December 2005. 
2.4 Inclusion criteria: 
Cases of breast cancer with full records and 
histopathological slides 
2.5 Exclusion criteria: 
Cases with deficient records (missed request forms) or 
missed histopathological slides. 
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2.6 Data collection: 
Data were collected from the patients request forms into a 
pre-designed questionnaire with detailed personal, clinical and 
pathological data. The slides were collected and reviewed to confirm 
the diagnosis of breast cancer, to determine the histological type 
using the WHO classification of breast cancer and to grade the 
tumor using the modified Bloom's Richardson's grading system .  
2.7 Data analysis and statistics: 
The data were analyzed electronically using computer 
program SPSS version 10.   
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RESULTS 
The total number of patients with breast cancer during the 
study period was 364; 64 of them had missed slides and 
consequently excluded from the study. The remainders (300) 
patients were selected and studied. 
1-3 Characteristics of the studied patients: 
1-3-1 Age distribution: 
The age of the studied patients ranged from 21 years to 77 
years, with a mean of 44.5± 13.7 years. 37.3% were below the age 
of 40 years of age. The age group with highest frequency was (35-
44) years (Figure1).   
3-1-2 Sex distribution of the patients: 
Two hundred and sixty two (87.3%) of the patients were 
females, compared to 38 (12.7%) males (Figure 2). Thus, the male 
to female ratio was 1:6.89.IDC was diagnosed in 34 (89.5%) of the 
males and in 228 (87.0%) of the female. While ILC was found in only 
one male (2.6%) compared to ten cases in females (3.2%). 
Statistical analysis did not approve correlation between the gender 
of the patient and the histological type of the tumor (P. value .784). 
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48% of males underwent simple mastectomy compared with 17% of 
the females. On the other hand, lumpectomy was performed more in 
females (29% of them) than in males (8.4% of them) .This 
relationship was significant (P value 0.00). (Figure 8) illustrates the 
relationship between the sex of the patient and the type of operation.  
3-1-3 Residence distribution in breast cancer: 
Concerning the residence of the patients, one hundred and 
twenty six (42%) of them came from the central regions including 
Khartoum and the four central states. Eighty one (27%) patients 
were from the northern region. The West, the East and the South 
were represented with thirty (10%), twenty four (08%) and eighteen 
(06%) patients respectively. In twenty one patients (07% of the 
cases) the residency was not stated in the request form (Figure4). 
3-2 Distribution of the clinical symptoms among 
studied patients: 
The various clinical presentations of the breast   cancer in 
the studied group were shown in the table (1). All of the patients 
(100%) had breast mass or lump. Come second is pain which was 
recorded in sixty three (21%) cases. Nipple retraction was found in 
thirty nine (13%) cases, while skin ulceration and weight loss were 
seen in twenty seven (09%) and twenty one (07%) patients 
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respectively. Other conditions (including the cases in which no 
symptom is recorded) were observed in fifty one (17%) of the cases. 
3-3 Site distribution of the breast cancer: 
Figure (5) demonstrates the site distribution of the breast 
cancer in the studied patients. Right sided and left sided cancer 
were found almost with equal frequencies, (42.7%) and (45.3%) 
respectively. The tumor was found bilateral in (3%) of the cases. 
Again, no information concerning the site was given in (9%) of the 
set up.  
3-4 Type of operation: 
Five modes of operation were used to obtain the specimen 
from the studied patients. The most frequently used procedure was 
radical mastectomy with axillary clearance (42.7%). Lumpectomy 
was performed in (28.3%) and simple mastectomy in (21.3%) of the 
cases. Quadrantectomy and core needle biopsy were both rare 
options (three cases for each). The type was not mentioned in 
(5.3%) of the cases (Table 2).          
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3-5 Histopathological characteristics of BC 
among the studied patients: 
3-5-1 Histological types: 
The diagnosis of breast cancer in this study is based solely 
on the histopathological examination of the surgical specimens.  
The vast majority (95.0%) were invasive tumors, while non 
invasive carcinoma including DCIS and LCIS constituted only (5.0%) 
of the cases (Figure 7).  
IDC was the predominant histological types; seen in (87.3%) 
of cases. Come second is ILC (3.7%). Ductal carcinoma in situ was 
diagnosed in (4.0%) of the cases. Other histological patterns include 
papillary carcinoma (2%), mucinous carcinoma (0.7%), lobular 
carcinoma in situ (1%), malignant phyllodes (0.7) % tumors and 
tubular carcinoma (0.7%) (Figure 6) 
 3-5-2 Grading: 
Modified Bloom's and Richardson's grading system was 
applied in this study. The majority of the cases (53.3%) were 
designed as grade 3 in this scale, followed by grade 2 (34%%) and 
lastly grade 1(12.7%) (Table 3) 
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Table 1: Clinical presentations of breast cancer among  
the study population 
Clinical presentation  Frequency Percentage 
Breast lump 300 100%  
Pain 63 21%  
Nipple discharge  30  10% 
Skin ulceration  27  9%  
Nipple retraction  39  13%  
Weight loss  21 7%  
Others  51 17% 
Total  300 100.0% 
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Table 2: Type of operations performed to the study population 
 
Type of operation   Frequency Percentage 
Mastectomy plus axillary clearance 128  42.7% 
Simple mastectomy  64 21.3%  
Lumpectomy  85 28.3% 
Quadrantectomy  3 1.0%  
Core biopsy  3 1.0% 
Not stated  17  5.7% 
Total  300 100.0% 
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Table 3: Grading scores for breast cancer among  
the study population 
Grade Frequency Percentage 
I 38 12.7%  
II 102 34%  
III 160 53.3%  
              Total  300 100.0% 
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Fig. 2:  Sex distribution of the study population
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Figure (3): Age specific incidence rate of BC in males and 
females among the study group 
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Fig. 5: Site distribution of breast cancer among the study 
population
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Fig. 7: Frequencies of invasive and non-
invasive cancers among the study population
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Figure(9) Invasive ductal carcinoma .Tubular formation          
Grade 1(H&E X 40)   
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                Figure(10) Invasive lobular carcinoma, Indian file 
pattern.  
(H&E X 40) 
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Figure (11): Ductal carcinoma in situ(DCIS) Cribriform pattern 
(H&E X 40)  
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Figure (12) Lobular carcinoma in situ 
(H&E X40) 
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Figure (13) Tubular carcinoma            
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Figure(14) Mucinous carcinoma of the breast 
(H&E X 40) 
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Figure (15) Invasive ductal carcinoma: mitotic figures.                   
                (H&E X 60) 
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Figure (16) Malignant phyllodes tumor  
H&E (X40) 
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DISCUSSION 
This study is a retrospective descriptive one addressed to the 
breast cancer in Sudanese patients. It was carried out in the period 
from January 2002 to December 2005 and includes analysis of 300 
cases. 
The epidemiological, clinical and pathological characteristics 
of breast cancer has been an area of great interest to many 
researchers especially in  Africa and the developing countries where 
it has been  scoring rising incidences, despite the fact  that it is lower 
than in more affluent societies. (5) 
In our country, there has been significant increase in all 
cancers incidences, the leading one being breast cancer, which 
reached alarming levels during the last decade. (4) This can be 
attributed, at least in part, to the trends in the Sudanese society 
towards urbanization and socioeconomic advances, which are linked 
to predisposition to this disease . In addition, increased medical 
awareness among people rendered them more readily seek advice 
and thence increased discovered cases. However, up to now there 
is no satisfactory and reliable data on the absolute cancer rates in 
Sudan. 
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This study encountered many difficulties and limitations due 
to the quality of the registered data on which the study was based, in 
particular the undetailed history and the clinical information 
necessary to assess the stage of the cancer. So caution should be 
taken when the results are interpreted with the international data. 
In regard to sex distribution of the breast cancer, the results 
of this study can be read with those carried out in Africa sub-
Saharan countries, with higher proportion of BC among males than 
in the global ratio. (3,16,42)  However, female predominance is still the 
rule, with females figure of (87.3 %) and males (21.7 %).This can 
easily  be explained on the back ground of the anatomical and 
physiological genders differences entailed in the pathogenesis of 
this cancer. (21, 24)  Statistical analysis showed significant influence of 
the sex on the type of operations. But there was no relation between 
the genders of the patients and the histological type, in contrast to 
the general believes that lobular carcinoma tends to predelicate to 
males. (9)  
In this study the mean age of the patients was found to be 
44.5 ±13 years. This is not much different from the mean age of BC 
in many Arab countries (117) and Sub Saharan African countries. (42)  It 
is more than twelve years younger than the age of 57 years 
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currently accepted for the Western communities. (15, 44) In addition, 
BC was found more frequent in the age group (35-44). Furthermore, 
(37.3%) of the patients in our set up were below the age of 40 years. 
This observation should alert the clinicians in our country to be more 
cautious in managing breast lumps especially in the younger age 
groups. 
Regarding the residency distribution, the majority (42%) of 
the patients came from the central regions (including the capital 
Khartoum and the four central states), the least frequent place of 
origin being the most remote states. This can readily be explained 
on the basis of the demographic and economic characteristics of the 
Sudanese population, in that most of the Sudanese are clustered in 
the big towns and also the unjustified focusing of the medical service 
in the capital. In addition, many people particularly in the rural areas 
fail o reach hospitals for diagnosis and treatment, not only because 
of lack of transport, but also due to their poor socioeconomic status 
and prevalence of some taboos as reliance and believes on herbal 
and spiritual medicine. However, the detailed social history was 
omitted from the records in most cases so was not analysed.  
Special attention should be paid to the disproportional high 
rate of BC in the patients from the North (27%). Further 
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demographical and environmental studies are highly recommended 
in that part of the country. 
  In this study, the results are in agreement with the literature 
regarding the occurrence of BC in almost equal rates in right 
(42.7%) and left(45.3%) breast(6). Bilateral BC was recorded in only 
(3%) of the patients.  
The present study found that all (100%) of the cases had at 
least on symptom at the time of diagnosis. Absence (00%) of 
asymptomatic BC patient highlights the negligibility of the role of 
cancer screening program, if any, in contrast to the situation in the 
developed countries. (87, 90)   
Moreover, higher proportions than what is internationally 
accepted of patients presented with signs of advanced BC such as 
skin ulcerations (09%) and nipple changes (13%). This may be due 
to social and cultural factors. Sudanese females are usually too 
reluctant to report small beast lumps for clinical examination. Again, 
this indicates that any effective future screening program is likely to 
improve dramatically the dim picture imposed by this dreadful 
dilemma. 
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The most frequent (43%) type of operation in our set up was 
radical mastectomy with axillary clearance, with higher proportion of 
this option among the elder age groups (86% in patients above sixty 
compared to 20% in patient under thirty five years).  Conservative 
surgery tends to be done in younger age groups. For instance, 
lumpectomy was performed in 39% of patient under thirty five in 
contrasts to only 6% in patients above sixty five years. Statistical 
analysis proved this relationship between the age of the patient and 
the mode of surgical therapy (P value 0.00).Core biopsy was done in 
Only 6 patients (2%). This is apparently due to the fact that it is only 
a diagnostic procedure in contrasts to the other options which are 
mainly therapeutic.  
On the view of the limitations of this study, only eight 
histological types of BC were encountered in the studied population. 
The vast majority (87%) was diagnosed as IDC. This result generally 
agrees with   many literature values in the developing countries.  (117, 
3) Invasive lobular carcinoma was seen in (3.7%) of the cases. Non 
invasive cancers (DCIS &LCIS) in this study showed markedly lower 
frequency (5%) in comparison to the western population. Again, 
screening may play a role in this point. Other histological types are 
all rare and include papillary carcinoma(2.0%),tubular carcinoma 
 
 
62
(0.7%), mucinous carcinoma (0.7%) and malignant phyllodes tumor 
(0.7%).In general, the histological types had no specific predilection 
for any age group(P. value 0.848) or  gender (P. value 0.783) . 
Most of the patients in this study (51%) were assigned as 
high grade  carcinoma (grade 3 in modified Bloom’s and  
Richardson’s system),  further highlighting  the aggressive nature of 
BC, in view that many patients came at later clinical stage of the 
tumor judged by tumor size, involvement of the lymph nodes and 
systemic metastasis. Unfortunately, our study could not assess the 
later important parameters due to intractable deficiency in the 
recorded data.  
So further work is needed to shed more light on the natural 
history of breast carcinoma in Sudanese patients and probably a 
collaborative multicenter study which includes all oncological centers 
in the county can fulfill this goal.     
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CONCLUTION 
• Regardless the limitations of this study, it indicated that our country 
shares many BC clinical and pathological characteristics in 
common with other developing countries and in contrasts to the 
western or developed countries.  
• These characteristics include the trend toward a greater incidence 
in younger age groups, a higher male- female ratio and higher 
frequencies of clinical and pathological indicators of more 
aggressiveness of the tumor. 
• The study identified only eight histological types of BC, namely: 
ICD, ILC, DCIS, LCIS, medullary carcinoma, papillary carcinoma, 
mucinous carcinoma and malignant phyllodes tumors.   
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RECOMMENDATIONS 
• Further in- depth studies are highly recommended to be carried out 
for more evaluation of risk factors and to find out the cause of high 
rates of the disease in this country, especially the Central and 
Northern regions. 
• Implementation and community promotion of breast cancer 
screening program for early detection and better prognosis. 
• Establishment of specialized breast centers and clinics to improve 
the screening, diagnosis and treatment services. 
• Improvement of cancer reporting and registration activities.   
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